trial · primary record
Zongertinib
Metastatic Breast Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 910 |
| Primary completion | 2029-01-08 |
| Primary endpoint | Dose escalation (Phase Ib): Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period |
| Registry ID | NCT06324357 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:17.400Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06324357
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- ZONGERTINIB · approval
- Zongertinib · compound